Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to E/C/F/TAF in virologically suppressed adults with archived M184V/I
2015-002710-74Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide in Human immunodeficiency virus infection type 1, sponsored by Gilead Sciences. Primary endpoint: HIV-1 RNA suppression at Week 12. Started Oct 2015; status: completed.
02
Drugs
elvitegravircobicistatemtricitabinetenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2015-002710-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002710-74.